CN108902989A - 一种辅助改善心脑血管疾病的人参肽及其制备方法 - Google Patents
一种辅助改善心脑血管疾病的人参肽及其制备方法 Download PDFInfo
- Publication number
- CN108902989A CN108902989A CN201810646694.4A CN201810646694A CN108902989A CN 108902989 A CN108902989 A CN 108902989A CN 201810646694 A CN201810646694 A CN 201810646694A CN 108902989 A CN108902989 A CN 108902989A
- Authority
- CN
- China
- Prior art keywords
- parts
- ginseng
- cerebrovascular disease
- cardiovascular
- auxiliary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 title claims abstract description 115
- 235000003140 Panax quinquefolius Nutrition 0.000 title claims abstract description 115
- 235000008434 ginseng Nutrition 0.000 title claims abstract description 115
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 63
- 208000026106 cerebrovascular disease Diseases 0.000 title claims abstract description 53
- 230000002526 effect on cardiovascular system Effects 0.000 title claims abstract description 53
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 52
- 238000002360 preparation method Methods 0.000 title claims abstract description 34
- 241000208340 Araliaceae Species 0.000 title abstract 5
- 102000004190 Enzymes Human genes 0.000 claims abstract description 26
- 108090000790 Enzymes Proteins 0.000 claims abstract description 26
- 230000007071 enzymatic hydrolysis Effects 0.000 claims abstract description 5
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 claims abstract description 5
- 240000004371 Panax ginseng Species 0.000 claims description 110
- 108091005804 Peptidases Proteins 0.000 claims description 40
- 239000000284 extract Substances 0.000 claims description 39
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims description 36
- 239000000203 mixture Substances 0.000 claims description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 30
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 claims description 28
- 239000003814 drug Substances 0.000 claims description 28
- 108010038983 glycyl-histidyl-lysine Proteins 0.000 claims description 28
- 235000009419 Fagopyrum esculentum Nutrition 0.000 claims description 26
- 244000017020 Ipomoea batatas Species 0.000 claims description 26
- 235000002678 Ipomoea batatas Nutrition 0.000 claims description 26
- 239000004365 Protease Substances 0.000 claims description 24
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 24
- 150000001875 compounds Chemical class 0.000 claims description 24
- 239000007788 liquid Substances 0.000 claims description 24
- 230000009849 deactivation Effects 0.000 claims description 23
- 239000012530 fluid Substances 0.000 claims description 21
- 229960003080 taurine Drugs 0.000 claims description 18
- MSWZFWKMSRAUBD-UHFFFAOYSA-N 2-Amino-2-Deoxy-Hexose Chemical compound NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims description 16
- 102000035195 Peptidases Human genes 0.000 claims description 16
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 16
- 108010019077 beta-Amylase Proteins 0.000 claims description 16
- 238000001035 drying Methods 0.000 claims description 16
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 16
- 235000013824 polyphenols Nutrition 0.000 claims description 16
- 108091008146 restriction endonucleases Proteins 0.000 claims description 16
- 239000006228 supernatant Substances 0.000 claims description 16
- 239000002253 acid Substances 0.000 claims description 14
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 13
- 229930195729 fatty acid Natural products 0.000 claims description 13
- 239000000194 fatty acid Substances 0.000 claims description 13
- 150000004665 fatty acids Chemical class 0.000 claims description 13
- 244000242323 Anchusa officinalis Species 0.000 claims description 11
- 235000017847 Anchusa officinalis Nutrition 0.000 claims description 11
- 241001474374 Blennius Species 0.000 claims description 11
- 240000002853 Nelumbo nucifera Species 0.000 claims description 11
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims description 11
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims description 11
- 235000003283 Pachira macrocarpa Nutrition 0.000 claims description 11
- 235000014364 Trapa natans Nutrition 0.000 claims description 11
- 235000009165 saligot Nutrition 0.000 claims description 11
- 210000000582 semen Anatomy 0.000 claims description 11
- 240000006766 Cornus mas Species 0.000 claims description 10
- 235000009811 Momordica charantia Nutrition 0.000 claims description 10
- 240000001910 Momordica cochinchinensis Species 0.000 claims description 10
- 235000009812 Momordica cochinchinensis Nutrition 0.000 claims description 10
- 235000018365 Momordica dioica Nutrition 0.000 claims description 10
- 240000001341 Reynoutria japonica Species 0.000 claims description 10
- 235000018167 Reynoutria japonica Nutrition 0.000 claims description 10
- 241001165494 Rhodiola Species 0.000 claims description 10
- 235000013399 edible fruits Nutrition 0.000 claims description 10
- 210000003101 oviduct Anatomy 0.000 claims description 10
- 235000005979 Citrus limon Nutrition 0.000 claims description 8
- 244000131522 Citrus pyriformis Species 0.000 claims description 8
- -1 pectase Proteins 0.000 claims description 8
- 238000000926 separation method Methods 0.000 claims description 8
- 239000002893 slag Substances 0.000 claims description 8
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 8
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- 238000004140 cleaning Methods 0.000 claims description 7
- 238000000605 extraction Methods 0.000 claims description 3
- 240000008620 Fagopyrum esculentum Species 0.000 claims 4
- 244000269722 Thea sinensis Species 0.000 claims 3
- 240000001085 Trapa natans Species 0.000 claims 3
- 241000191896 Rana sylvatica Species 0.000 claims 1
- 238000012360 testing method Methods 0.000 abstract description 28
- 230000000694 effects Effects 0.000 abstract description 11
- 238000009098 adjuvant therapy Methods 0.000 abstract description 9
- 238000000034 method Methods 0.000 abstract description 8
- 235000016709 nutrition Nutrition 0.000 abstract description 4
- 230000035764 nutrition Effects 0.000 abstract description 4
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 235000013343 vitamin Nutrition 0.000 abstract description 2
- 229940088594 vitamin Drugs 0.000 abstract description 2
- 229930003231 vitamin Natural products 0.000 abstract description 2
- 239000011782 vitamin Substances 0.000 abstract description 2
- 150000003722 vitamin derivatives Chemical class 0.000 abstract description 2
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 241000219051 Fagopyrum Species 0.000 description 22
- 241000700159 Rattus Species 0.000 description 15
- 241001122767 Theaceae Species 0.000 description 15
- 229940079593 drug Drugs 0.000 description 11
- 241001083492 Trapa Species 0.000 description 8
- 239000002994 raw material Substances 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 5
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 231100001252 long-term toxicity Toxicity 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 2
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000005311 nuclear magnetism Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- UUQMNUMQCIQDMZ-UHFFFAOYSA-N betahistine Chemical compound CNCCC1=CC=CC=N1 UUQMNUMQCIQDMZ-UHFFFAOYSA-N 0.000 description 1
- 229960004536 betahistine Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000015111 chews Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940093181 glucose injection Drugs 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000003516 hyperlipidaemic effect Effects 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940090044 injection Drugs 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 229960003827 isosorbide mononitrate Drugs 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 239000009692 xuesetong Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
- A23J1/006—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from vegetable materials
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J3/00—Working-up of proteins for foodstuffs
- A23J3/30—Working-up of proteins for foodstuffs by hydrolysis
- A23J3/32—Working-up of proteins for foodstuffs by hydrolysis using chemical agents
- A23J3/34—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes
- A23J3/346—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes of vegetable proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/10—Products from fruits or vegetables; Preparation or treatment thereof of tuberous or like starch containing root crops
- A23L19/105—Sweet potatoes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/65—Amphibians, e.g. toads, frogs, salamanders or newts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/41—Crassulaceae (Stonecrop family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/89—Cyperaceae (Sedge family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/13—Preparation or pretreatment of starting material involving cleaning, e.g. washing or peeling
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/17—Preparation or pretreatment of starting material involving drying, e.g. sun-drying or wilting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明公开了一种辅助改善心脑血管疾病的人参肽及其制备方法。本发明提供的辅助改善心脑血管疾病的人参肽提升本发明人参肽对心脑血管疾病的辅助治疗作用,提供了丰富营养的同时,强化了患者急需的维生素、微量元素和氨基酸,在经过反复试验所得的配方范围内,这些营养物质可以协同作用,达到很好的营养和辅助治疗的效果,并在特定配比下取得了意想不到的辅助治疗效果;酶解中酶的组合和用量的选择,使得酶解效率和酶解程度高,且酶解物中氨基化学物的种类和数量多,口感好;本发明提供的辅助改善心脑血管疾病的人参肽的制备方法工艺先进、工序合理、可操作性强,易于工业化生产。
Description
技术领域
本发明涉及保健品技术领域,更具体地,涉及一种辅助改善心脑血管疾病的人参肽及其制备方法。
背景技术
心脑血管疾病就是心脏血管和脑血管的疾病统称。心脑血管疾病是一种严重威胁人类,特别是50岁以上中老年人健康的常见病,全世界每年死于心脑血管疾病的人数高达1500万人,居各种死因首位。目前心脑血管疾病的治疗多采取药物、手术等西医疗法,往往副作用大,治疗效果不是很好,病人容易并发多种影响生活质量的疾病。
因此现在对心脑血管疾病专家往往建议以预防为主,特别是注意饮食的调节,一旦患病,更要注重饮食的辅助治疗,并且越来越重视中药的辅助治疗作用。其中,小分子人参肽是中医和高科技生物的完美结合,纯绿色养生技术,能让心脑血管疾病患者获得健康。
本发明正是通过多种可以调节心脑血管疾病的药材,搭配小分子人参肽,强化对心脑血管疾病有益的营养元素,并添加对心脑血管疾病有治疗作用的中药成分,从而开发制成一种用于预防和辅助治疗心脑血管疾病的全营养配方保健食品,已经通过临床试验证明对心脑血管疾病的辅助治疗有良好的效果。
发明内容
本发明的一个目的是提供一种辅助改善心脑血管疾病的人参肽的新技术方案。
本发明的另一个目的是提供一种人参肽的制备方法的新技术方案。
本发明的另一个目的是提供一种辅助改善心脑血管疾病的人参肽的制备方法的新技术方案。
根据本发明的第一方面,提供了一种辅助改善心脑血管疾病的人参肽,所述人参肽主要由下列重量份的组分制备而成:
人参肽粉65-80份、荞麦5-9份、中药提取物11-15份、紫薯4-6份、脂肪酸1-3份、林蛙油1-3份、茶多酚2-5份、牛磺酸1-3份、D-氨基葡萄糖盐酸盐0.3-0.5份。
优选地,所述人参肽主要由下列重量份的组分制备而成:
人参肽粉72份、荞麦6份、中药提取物14份、紫薯5份、脂肪酸2 份、林蛙油2份、茶多酚4份、牛磺酸1.5份、D-氨基葡萄糖盐酸盐0.4 份。
优选地,所述中药提取物由下列重量份的组分制备而成:
苦瓜11-13份、薏苡仁9-12份、何首乌7-10份、荸荠皮5-7份、毛连菜4-6份、枸杞子10-14份、山萸肉11-14份、莲藕11-13份、红景天 6-8份、海藻5-8份、熟地8-11份、黄精8-12份。
优选地,所述中药提取物由下列重量份的组分制备而成:
苦瓜12份、薏苡仁10份、何首乌8份、荸荠皮6份、毛连菜5份、枸杞子13份、山萸肉12份、莲藕12份、红景天7份、海藻7份、熟地9 份、黄精9份。
根据本发明的第二方面,提供了一种人参肽粉的制备方法,包括以下步骤:
(1)将人参洗干净晾干后切成5cm厚度的片状,进行超微粉碎,过 400目筛;
(2)将步骤(1)制得的人参粉加入配制罐中,加入5倍重量的水,加入蛋白质水解酶酶解2h,然后升温至95℃,灭酶30min,放冷;加入碳酸氢钠调节pH值至6.0,加入β-淀粉酶和复合蛋白酶的混合物酶解2h,所述复合蛋白酶采用Protamex,然后升温至95℃,灭酶30min,放冷;加入柠檬酸调节pH值至4.0,加入果胶酶和内切酶的混合物酶解2h,然后升温至95℃,灭酶30min,放冷,得到酶解液;所述蛋白质水解酶、β- 淀粉酶、复合蛋白酶、果胶酶、内切酶和人参粉的质量比为11:3:5:3:6:960;
(3)将酶解液通过离心机进行液、渣分离,取其上清液,将上清液pH 值调节至6.0-7.5,浓缩,烘干,得到人参肽粉。
根据本发明的第三方面,提供了一种辅助改善心脑血管疾病的人参肽的制备方法,包括以下步骤:
(1)将荞麦和紫薯洗净、烘干、磨碎,过100目筛,备用;
(2)按照配方量称取苦瓜、薏苡仁、何首乌、荸荠皮、毛连菜、枸杞子、山萸肉、莲藕、红景天、海藻、熟地和黄精,粉碎后混合均匀,清洗后放置于提取罐中加水提取两次,第一次加组合物总重量8倍重量的水,第二次加组合物总重量6倍重量的水,每次提取2小时,制得药液,将药液滤过,合并两次煎煮的药液,减压浓缩至60℃时相对密度为1.0;减压浓缩条件为60-70℃,0.05-0.07MPa,即得中药提取物;
(3)按配方量准确称取上述各种组分:中药提取物、人参肽粉、荞麦、紫薯、脂肪酸、林蛙油、茶多酚、牛磺酸和D-氨基葡萄糖盐酸盐,充分搅拌均匀,即得辅助改善心脑血管疾病的人参肽。
本发明提供的辅助改善心脑血管疾病的人参肽提升本发明人参肽对心脑血管疾病的辅助治疗作用,提供了丰富营养的同时,强化了患者急需的维生素、微量元素和氨基酸,在经过反复试验所得的配方范围内,这些营养物质可以协同作用,达到很好的营养和辅助治疗的效果,并在特定配比下取得了意想不到的辅助治疗效果;酶解中酶的组合和用量的选择,使得酶解效率和酶解程度高,且酶解物中氨基化学物的种类和数量多,口感好;本发明提供的辅助改善心脑血管疾病的人参肽的制备方法工艺先进、工序合理、可操作性强,易于工业化生产。
具体实施方式
实施例1
1、中药提取物的制备:
(1)称取以下重量克数的中药:苦瓜12g、薏苡仁10g、何首乌8g、荸荠皮6g、毛连菜5g、枸杞子13g、山萸肉12g、莲藕12g、红景天7g、海藻7g、熟地9g、黄精9g。
(2)将步骤(1)的中药粉碎后混合均匀,清洗后放置于提取罐中加水提取两次,第一次加组合物总重量8倍重量的水,第二次加组合物总重量6倍重量的水,每次提取2小时,制得药液,将药液滤过,合并两次煎煮的药液,减压浓缩至60℃时相对密度为1.0;减压浓缩条件为65℃,0.06MPa,即得中药提取物。
2、人参肽粉的制备:
(1)将人参洗干净晾干后切成5cm厚度的片状,进行超微粉碎,过 400目筛;
(2)将步骤(1)制得的人参粉加入配制罐中,加入5倍重量的水,加入蛋白质水解酶酶解2h,然后升温至95℃,灭酶30min,放冷;加入碳酸氢钠调节pH值至6.0,加入β-淀粉酶和复合蛋白酶的混合物酶解2h,所述复合蛋白酶采用Protamex,然后升温至95℃,灭酶30min,放冷;加入柠檬酸调节pH值至4.0,加入果胶酶和内切酶的混合物酶解2h,然后升温至95℃,灭酶30min,放冷,得到酶解液;所述蛋白质水解酶、β- 淀粉酶、复合蛋白酶、果胶酶、内切酶和人参粉的质量比为11:3:5:3: 6:960;
(3)将酶解液通过离心机进行液、渣分离,取其上清液,将上清液pH 值调节至7.0,浓缩,烘干,得到人参肽粉。
3、辅助改善心脑血管疾病的人参肽的制备:
(1)称取以下重量克数的原料:人参肽粉72g、荞麦6g、中药提取物 14g、紫薯5g、脂肪酸2g、林蛙油2g、茶多酚4g、牛磺酸1.5g、D-氨基葡萄糖盐酸盐0.4g;
(2)将荞麦和紫薯洗净、烘干、磨碎,过100目筛,备用;
(3)按配方量准确称取上述各种组分:中药提取物、人参肽、荞麦、紫薯、脂肪酸、林蛙油、茶多酚、牛磺酸和D-氨基葡萄糖盐酸盐,充分搅拌均匀,即得辅助改善心脑血管疾病的人参肽。
实施例2
1、中药提取物的制备:
(1)称取以下重量克数的中药:苦瓜11g、薏苡仁9g、何首乌7g、荸荠皮5g、毛连菜4g、枸杞子10g、山萸肉11g、莲藕11g、红景天6g、海藻5g、熟地8g、黄精8g。
(2)将步骤(1)的中药粉碎后混合均匀,清洗后放置于提取罐中加水提取两次,第一次加组合物总重量8倍重量的水,第二次加组合物总重量6倍重量的水,每次提取2小时,制得药液,将药液滤过,合并两次煎煮的药液,减压浓缩至60℃时相对密度为1.0;减压浓缩条件为60℃,0.05MPa,即得中药提取物。
2、人参肽粉的制备:
(1)将人参洗干净晾干后切成5cm厚度的片状,进行超微粉碎,过 400目筛;
(2)将步骤(1)制得的人参粉加入配制罐中,加入5倍重量的水,加入蛋白质水解酶酶解2h,然后升温至95℃,灭酶30min,放冷;加入碳酸氢钠调节pH值至6.0,加入β-淀粉酶和复合蛋白酶的混合物酶解2h,所述复合蛋白酶采用Protamex,然后升温至95℃,灭酶30min,放冷;加入柠檬酸调节pH值至4.0,加入果胶酶和内切酶的混合物酶解2h,然后升温至95℃,灭酶30min,放冷,得到酶解液;所述蛋白质水解酶、β- 淀粉酶、复合蛋白酶、果胶酶、内切酶和人参粉的质量比为11:3:5:3: 6:960;
(3)将酶解液通过离心机进行液、渣分离,取其上清液,将上清液pH 值调节至6.0,浓缩,烘干,得到人参肽粉。
3、辅助改善心脑血管疾病的人参肽的制备:
(1)称取以下重量克数的原料:人参肽粉65g、荞麦5g、中药提取物11g、紫薯4g、脂肪酸1g、林蛙油1g、茶多酚2g、牛磺酸1g、D-氨基葡萄糖盐酸盐0.3g。
(2)将荞麦和紫薯洗净、烘干、磨碎,过100目筛,备用;
(3)按配方量准确称取上述各种组分:中药提取物、人参肽、荞麦、紫薯、脂肪酸、林蛙油、茶多酚、牛磺酸和D-氨基葡萄糖盐酸盐,充分搅拌均匀,即得辅助改善心脑血管疾病的人参肽。
实施例3
1、中药提取物的制备:
(1)称取以下重量克数的中药:苦瓜13g、薏苡仁12g、何首乌10g、荸荠皮7g、毛连菜6g、枸杞子14g、山萸肉14g、莲藕13g、红景天8g、海藻8g、熟地11g、黄精12g;
(2)将步骤(1)的中药粉碎后混合均匀,清洗后放置于提取罐中加水提取两次,第一次加组合物总重量8倍重量的水,第二次加组合物总重量6倍重量的水,每次提取2小时,制得药液,将药液滤过,合并两次煎煮的药液,减压浓缩至60℃时相对密度为1.0;减压浓缩条件为70℃,0.07MPa,即得中药提取物。
2、人参肽粉的制备:
(1)将人参洗干净晾干后切成5cm厚度的片状,进行超微粉碎,过 400目筛;
(2)将步骤(1)制得的人参粉加入配制罐中,加入5倍重量的水,加入蛋白质水解酶酶解2h,然后升温至95℃,灭酶30min,放冷;加入碳酸氢钠调节pH值至6.0,加入β-淀粉酶和复合蛋白酶的混合物酶解2h,所述复合蛋白酶采用Protamex,然后升温至95℃,灭酶30min,放冷;加入柠檬酸调节pH值至4.0,加入果胶酶和内切酶的混合物酶解2h,然后升温至95℃,灭酶30min,放冷,得到酶解液;所述蛋白质水解酶、β- 淀粉酶、复合蛋白酶、果胶酶、内切酶和人参粉的质量比为11:3:5:3: 6:960;
(3)将酶解液通过离心机进行液、渣分离,取其上清液,将上清液pH 值调节至7.5,浓缩,烘干,得到人参肽粉。
3、辅助改善心脑血管疾病的人参肽的制备:
(1)称取以下重量克数的原料:人参肽粉80g、荞麦9g、中药提取物 15g、紫薯6g、脂肪酸3g、林蛙油3g、茶多酚5g、牛磺酸3g、D-氨基葡萄糖盐酸盐0.5g;
(2)将荞麦和紫薯洗净、烘干、磨碎,过100目筛,备用;
(3)按配方量准确称取上述各种组分:中药提取物、人参肽、荞麦、紫薯、脂肪酸、林蛙油、茶多酚、牛磺酸和D-氨基葡萄糖盐酸盐,充分搅拌均匀,即得辅助改善心脑血管疾病的人参肽。
对照例1
1、人参肽粉的制备:
(1)将人参洗干净晾干后切成5cm厚度的片状,进行超微粉碎,过 400目筛;
(2)将步骤(1)制得的人参粉加入配制罐中,加入5倍重量的水,加入蛋白质水解酶酶解2h,然后升温至95℃,灭酶30min,放冷;加入碳酸氢钠调节pH值至6.0,加入β-淀粉酶和复合蛋白酶的混合物酶解2h,所述复合蛋白酶采用Protamex,然后升温至95℃,灭酶30min,放冷;加入柠檬酸调节pH值至4.0,加入果胶酶和内切酶的混合物酶解2h,然后升温至95℃,灭酶30min,放冷,得到酶解液;所述蛋白质水解酶、β- 淀粉酶、复合蛋白酶、果胶酶、内切酶和人参粉的质量比为11:3:5:3: 6:960;
(3)将酶解液通过离心机进行液、渣分离,取其上清液,将上清液pH 值调节至7.0,浓缩,烘干,得到人参肽粉。
2、辅助改善心脑血管疾病的人参肽的制备:
(1)称取以下重量克数的原料:人参肽粉72g、荞麦6g、紫薯5g、脂肪酸2g、林蛙油2g、茶多酚4g、牛磺酸1.5g、D-氨基葡萄糖盐酸盐0.4g;
(2)将荞麦和紫薯洗净、烘干、磨碎,过100目筛,备用;
(3)按配方量准确称取上述各种组分:人参肽、荞麦、紫薯、脂肪酸、林蛙油、茶多酚、牛磺酸和D-氨基葡萄糖盐酸盐,充分搅拌均匀,即得辅助改善心脑血管疾病的人参肽。
对照例2
1、中药提取物的制备:
(1)称取以下重量克数的中药:薏苡仁10g、荸荠皮6g、毛连菜5g、枸杞子13g、山萸肉12g、莲藕12g、红景天7g、海藻7g、熟地9g。
(2)将步骤(1)的中药粉碎后混合均匀,清洗后放置于提取罐中加水提取两次,第一次加组合物总重量8倍重量的水,第二次加组合物总重量6倍重量的水,每次提取2小时,制得药液,将药液滤过,合并两次煎煮的药液,减压浓缩至60℃时相对密度为1.0;减压浓缩条件为65℃,0.06MPa,即得中药提取物。
2、人参肽粉的制备:
(1)将人参洗干净晾干后切成5cm厚度的片状,进行超微粉碎,过 400目筛;
(2)将步骤(1)制得的人参粉加入配制罐中,加入5倍重量的水,加入蛋白质水解酶酶解2h,然后升温至95℃,灭酶30min,放冷;加入碳酸氢钠调节pH值至6.0,加入β-淀粉酶和复合蛋白酶的混合物酶解2h,所述复合蛋白酶采用Protamex,然后升温至95℃,灭酶30min,放冷;加入柠檬酸调节pH值至4.0,加入果胶酶和内切酶的混合物酶解2h,然后升温至95℃,灭酶30min,放冷,得到酶解液;所述蛋白质水解酶、β- 淀粉酶、复合蛋白酶、果胶酶、内切酶和人参粉的质量比为11:3:5:3: 6:960;
(3)将酶解液通过离心机进行液、渣分离,取其上清液,将上清液pH 值调节至7.0,浓缩,烘干,得到人参肽粉。
3、辅助改善心脑血管疾病的人参肽的制备:
(1)称取以下重量克数的原料:人参肽粉72g、荞麦6g、中药提取物 14g、紫薯5g、脂肪酸2g、林蛙油2g、茶多酚4g、牛磺酸1.5g、D-氨基葡萄糖盐酸盐0.4g;
(2)将荞麦和紫薯洗净、烘干、磨碎,过100目筛,备用;
(3)按配方量准确称取上述各种组分:中药提取物、人参肽、荞麦、紫薯、脂肪酸、林蛙油、茶多酚、牛磺酸和D-氨基葡萄糖盐酸盐,充分搅拌均匀,即得辅助改善心脑血管疾病的人参肽。
对照例3
1、中药提取物的制备:
(1)称取以下重量克数的中药:苦瓜12g、薏苡仁10g、何首乌8g、荸荠皮6g、毛连菜5g、枸杞子13g、山萸肉12g、莲藕12g、红景天7g、海藻7g、熟地9g、黄精9g。
(2)将步骤(1)的中药粉碎后混合均匀,清洗后放置于提取罐中加水提取两次,第一次加组合物总重量8倍重量的水,第二次加组合物总重量6倍重量的水,每次提取2小时,制得药液,将药液滤过,合并两次煎煮的药液,减压浓缩至60℃时相对密度为1.0;减压浓缩条件为65℃,0.06MPa,即得中药提取物。
2、人参肽粉的制备:
(1)将人参洗干净晾干后切成5cm厚度的片状,进行超微粉碎,过 400目筛;
(2)将步骤(1)制得的人参粉加入配制罐中,加入5倍重量的水,加入蛋白质水解酶酶解2h,然后升温至95℃,灭酶30min,放冷;加入碳酸氢钠调节pH值至6.0,加入β-淀粉酶和复合蛋白酶的混合物酶解2h,所述复合蛋白酶采用Protamex,然后升温至95℃,灭酶30min,放冷;加入柠檬酸调节pH值至4.0,加入果胶酶和内切酶的混合物酶解2h,然后升温至95℃,灭酶30min,放冷,得到酶解液;所述蛋白质水解酶、β- 淀粉酶、复合蛋白酶、果胶酶、内切酶和人参粉的质量比为11:3:5:3: 6:960;
(3)将酶解液通过离心机进行液、渣分离,取其上清液,将上清液pH 值调节至7.0,浓缩,烘干,得到人参肽粉。
3、辅助改善心脑血管疾病的人参肽的制备:
(1)称取以下重量克数的原料:人参肽粉72g、荞麦6g、中药提取物 14g、紫薯5g、脂肪酸2g、茶多酚4g和牛磺酸1.5g;
(2)将荞麦和紫薯洗净、烘干、磨碎,过100目筛,备用;
(3)按配方量准确称取上述各种组分:中药提取物、人参肽、荞麦、紫薯、脂肪酸、茶多酚和牛磺酸,充分搅拌均匀,即得辅助改善心脑血管疾病的人参肽。
试验例1、毒性试验
(一)急性毒性试验
1.试验对象:健康SD大鼠
试验组50例,雄鼠,年龄5周龄;
对照组50例,雄鼠,年龄5周龄。
2.试验方法:
试验组:将本发明实施例制备的辅助改善心脑血管疾病的人参肽用生理盐水配制成65%浓度的溶液,给大鼠按一次40mL/kg灌胃,一日内连续两次,然后停药,停药后继续观察7天。
对照组:用生理盐水给大鼠按一次40mL/kg灌胃,一日内连续两次,然后停药,停药后继续观察7天。
3.统计方法:分别在试验1天、2天、3天、4天、5天、6天、7天,记录两组大鼠的死亡率及大鼠行为有无明显异常;在观察期结束后,于第8天处死大鼠,进行剖检,记录两组大鼠的脏器异常改变情况。
4.试验结果:
试验结果见表1。
表1.急性毒性试验结果
表1的比较结果如下:
由试验组和对照组的比较可知,本发明辅助改善心脑血管疾病的人参肽对大鼠没有急性毒性。
5.结论:本发明辅助改善心脑血管疾病的人参肽,安全度高,无急性毒性。
(二)长期毒性试验
1.试验对象:健康SD大鼠
试验组50例,雄鼠,年龄5周龄;
对照组50例,雄鼠,年龄5周龄。
2.试验方法:
试验组:将本发明实施例制备的辅助改善心脑血管疾病的人参肽溶解在水中灌胃,用药剂量以白鼠体重计,每日0.05g/kg,连续180天,停药后继续观察30天。
对照组:喂食与试验组一样且不含本发明中药组合物的食物,食物量也与试验组一样,并灌胃等量生理盐水,连续180天;随后的30天观察期期间,大鼠与试验组一样对待。
3.统计方法:分别在试验0天、30天、60天、90天、120天、150天、 180天、及观察期结束时,记录两组大鼠的死亡率及大鼠行为有无明显异常;在观察期结束后,处死大鼠,进行剖检,记录两组大鼠的饮食、饮水、体重增长和脏器异常改变情况。
4.试验结果:试验结果见表2。
表2.长期毒性试验结果
表2的比较结果如下:
由试验组和对照组的比较可知,本发明辅助改善心脑血管疾病的人参肽对大鼠无长期毒性;
5.结论:本发明辅助改善心脑血管疾病的人参肽,安全度高,无长期毒性。
试验例2临床效果试验
1、试验对象:
400例患者,分别患有高血压、高血脂、冠心病、脑血栓、脑供血不足和动脉硬化,每种病症患者都是50名,均按照标准诊断法予以确诊,并被心电图、脑电图、核磁、血液检查等证实。
2、试验方法:
(1)将患者随机的分为6个组,并且各种病症的患者在各组分布均匀。每组患者除对症进行治疗外,分别给予安慰剂(用淀粉制作的营养粉类似物)、实施例1制备的人参肽、实施例2制备的人参肽、实施例3制备的人参肽、实施例1制备的中药提取物、对照例1制备的人参肽、对照例2 制备的人参肽以及对照例3制备的人参肽。用量均为40g/次,一日三次,疗程为30天。
3、为便于对本发明营养粉辅助治疗效果的评价,减少干扰,每个患者的对症治疗就选择了尽可能简便有效的治疗方法,各种患者治疗方法如下:
(1)高血压患者:服用复方利血平片(石药集团中诺药业有限公司,国药准字H13024462)一次2片,一日3次。
(2)高血脂患者:服用阿托伐他汀钙片(北京嘉林药业股份有限公司,国药准字H19990258)一日1次,一次10-50mg(根据患者的病情适当调整)。
(3)冠心病患者:心绞痛发作时,硝酸甘油1片(每片0.3~0.5毫克)嚼碎后舌下含服服用;日常治疗服用单硝酸异山梨酯片(鲁南贝特制药有限公司,国药准字H10940039),一日2次,一次20-40mg(根据患者的病情适当调整)。
(4)脑血栓患者:血塞通注射液(昆明制药集团股份有限公司,国药准字Z53020662)静脉注射,一次200mg用5%葡萄糖注射液250稀释后缓缓滴注一日1次。
(5)脑供血不足患者:用盐酸倍他司汀注射液(亚宝药业太原制药有限公司,国药准字H20063089),肌内注射。一次10mg,一日2次。
(6)动脉硬化患者:硝苯地平缓释片(地奥集团成都药业股份有限公司,国药准字H10910052),20mg,每日1次;辛伐他汀胶囊(湖南正太金琥药业有限公司,国药准字H20010168),每次10mg,每日1次;阿司匹林肠溶片(沈阳奥吉娜药业有限公司,国药准字H20065051),每次 100mg,每日1次;三种药物同时服用。
4、试验结果评判标准:
(1)治愈:症状完全消失,体征指标完全恢复正常,并经心电图、脑电图、核磁、血液检查等确认,已经痊愈。
(2)有效:症状有不同程度改善或好转,体征指标有所好转,需继续用药治疗。
(3)无效:症状无任何改善或好转,甚至有发展之趋势。
5、试验结果:
经过30天的试验,试验结果统计如下表2所示:
表2试验结果统计表
6、试验结果分析:
由表2可以看出,本发明的辅助改善心脑血管疾病的人参肽在辅助治疗心脑血管疾病的时候发挥了巨大的作用,与对照组相比较,其余各组的总有效率均有明显的提高,治愈率均有增加,特别是对于最优配方的实施例1,效果更是十分显著。从表中还可以看出,单纯的使用中药提取物或者使用对照例1的不含中药提取物的人参肽,效果均不明显,而将两者按一定比例制成本发明的人参肽时,就显现出了出人意料的技术成果;另外,本发明的人参肽的各组分之间存在协同增效作用,能够提升产品对心脑血管疾病的改善和控制功效,当本发明提供的人参肽中的组分增加、减少或配量发生变化时,辅助治疗的效果显著的降低。
Claims (6)
1.一种辅助改善心脑血管疾病的人参肽,其特征在于,所述人参肽主要由下列重量份的组分制备而成:
人参肽粉65-80份、荞麦5-9份、中药提取物11-15份、紫薯4-6份、脂肪酸1-3份、林蛙油1-3份、茶多酚2-5份、牛磺酸1-3份、D-氨基葡萄糖盐酸盐0.3-0.5份。
2.根据权利要求1所述的辅助改善心脑血管疾病的人参肽,其特征在于,所述人参肽主要由下列重量份的组分制备而成:
人参肽粉72份、荞麦6份、中药提取物14份、紫薯5份、脂肪酸2份、林蛙油2份、茶多酚4份、牛磺酸1.5份、D-氨基葡萄糖盐酸盐0.4份。
3.根据权利要求1或2所述的辅助改善心脑血管疾病的人参肽,其特征在于,所述中药提取物由下列重量份的组分制备而成:
苦瓜11-13份、薏苡仁9-12份、何首乌7-10份、荸荠皮5-7份、毛连菜4-6份、枸杞子10-14份、山萸肉11-14份、莲藕11-13份、红景天6-8份、海藻5-8份、熟地8-11份、黄精8-12份。
4.根据权利要求3所述的辅助改善心脑血管疾病的人参肽,其特征在于,所述中药提取物由下列重量份的组分制备而成:
苦瓜12份、薏苡仁10份、何首乌8份、荸荠皮6份、毛连菜5份、枸杞子13份、山萸肉12份、莲藕12份、红景天7份、海藻7份、熟地9份、黄精9份。
5.一种如权利要求1或2所述的人参肽粉的制备方法,其特征在于,包括以下步骤:
(1)将人参洗干净晾干后切成5cm厚度的片状,进行超微粉碎,过400目筛;
(2)将步骤(1)制得的人参粉加入配制罐中,加入5倍重量的水,加入蛋白质水解酶酶解2h,然后升温至95℃,灭酶30min,放冷;加入碳酸氢钠调节pH值至6.0,加入β-淀粉酶和复合蛋白酶的混合物酶解2h,所述复合蛋白酶采用Protamex,然后升温至95℃,灭酶30min,放冷;加入柠檬酸调节pH值至4.0,加入果胶酶和内切酶的混合物酶解2h,然后升温至95℃,灭酶30min,放冷,得到酶解液;所述蛋白质水解酶、β-淀粉酶、复合蛋白酶、果胶酶、内切酶和人参粉的质量比为11:3:5:3:6:960;
(3)将酶解液通过离心机进行液、渣分离,取其上清液,将上清液pH值调节至6.0-7.5,浓缩,烘干,得到人参肽粉。
6.一种如权利要求3所述的辅助改善心脑血管疾病的人参肽的制备方法,其特征在于,包括以下步骤:
(1)将荞麦和紫薯洗净、烘干、磨碎,过100目筛,备用;
(2)按照配方量称取苦瓜、薏苡仁、何首乌、荸荠皮、毛连菜、枸杞子、山萸肉、莲藕、红景天、海藻、熟地和黄精,粉碎后混合均匀,清洗后放置于提取罐中加水提取两次,第一次加组合物总重量8倍重量的水,第二次加组合物总重量6倍重量的水,每次提取2小时,制得药液,将药液滤过,合并两次煎煮的药液,减压浓缩至60℃时相对密度为1.0;减压浓缩条件为60-70℃,0.05-0.07MPa,即得中药提取物;
(3)按配方量准确称取上述各种组分:中药提取物、人参肽粉、荞麦、紫薯、脂肪酸、林蛙油、茶多酚、牛磺酸和D-氨基葡萄糖盐酸盐,充分搅拌均匀,即得辅助改善心脑血管疾病的人参肽。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810646694.4A CN108902989A (zh) | 2018-06-21 | 2018-06-21 | 一种辅助改善心脑血管疾病的人参肽及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810646694.4A CN108902989A (zh) | 2018-06-21 | 2018-06-21 | 一种辅助改善心脑血管疾病的人参肽及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108902989A true CN108902989A (zh) | 2018-11-30 |
Family
ID=64421491
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810646694.4A Withdrawn CN108902989A (zh) | 2018-06-21 | 2018-06-21 | 一种辅助改善心脑血管疾病的人参肽及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108902989A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111616373A (zh) * | 2020-07-02 | 2020-09-04 | 西咸新区优恩生物科技股份有限公司 | 一种适用心脑调节人群的宇航民用营养配方 |
CN115474692A (zh) * | 2021-06-16 | 2022-12-16 | 法尔玛国际健康管理有限公司 | 一种调理女性内分泌功能的营养组合物 |
-
2018
- 2018-06-21 CN CN201810646694.4A patent/CN108902989A/zh not_active Withdrawn
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111616373A (zh) * | 2020-07-02 | 2020-09-04 | 西咸新区优恩生物科技股份有限公司 | 一种适用心脑调节人群的宇航民用营养配方 |
CN115474692A (zh) * | 2021-06-16 | 2022-12-16 | 法尔玛国际健康管理有限公司 | 一种调理女性内分泌功能的营养组合物 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101011561B (zh) | 黄连温胆汤现代中药口服制剂及其生产方法 | |
CN106606529A (zh) | 一种具有辅助降血糖功效的组合物及其制备方法和应用 | |
CN109393494A (zh) | 一种中老年用保健食品组合物及其应用 | |
CN101190280B (zh) | 梅树非果部分提取物的用途 | |
CN105707637A (zh) | 一种降糖固体饮料及其制备方法 | |
CN105267755A (zh) | 降糖口服液 | |
CN108902989A (zh) | 一种辅助改善心脑血管疾病的人参肽及其制备方法 | |
CN104800608B (zh) | 一种具有降血压功效的中草药组合物及其应用 | |
CN106173028A (zh) | 一种具有降血糖功效的保健茶及其制备方法 | |
CN116370556B (zh) | 一种活血祛瘀、益气安神的中药组合物及其制备方法 | |
CN1329049C (zh) | 降血糖、降血压的药物 | |
CN101293081B (zh) | 一种治疗高血脂症的药物及其制备方法 | |
CN106421581A (zh) | 一种用于治疗糖尿病的生物中药内服药及其制备方法 | |
CN106035849A (zh) | 一种降血压保健茶及其制备工艺 | |
CN100462085C (zh) | 一种调节血糖、血压和血脂的药品或保健食品片剂及其制备方法 | |
CN108935818A (zh) | 一种青钱柳叶保健饮料茶及其制备方法 | |
CN102178718B (zh) | 一种用于治疗糖尿病和防治心脑血管疾病的制剂 | |
KR100979882B1 (ko) | 금은화 추출물과 홍삼 추출물을 함유하는 당뇨병 예방 및치료용 조성물 | |
CN115137770A (zh) | 一种具有降血脂血压功效的中药产品制作方法 | |
CN100488546C (zh) | 降糖降脂降压、改善微循环及免疫的药剂及其制备方法 | |
CN106620245A (zh) | 一种降低空腹血糖及餐后血糖的沙棘叶五味丸及制备方法 | |
CN105998098A (zh) | 一种制备治疗糖尿病肾病的中药组合物的方法 | |
CN106474190A (zh) | 一种用于治疗ⅱ型糖尿病及并发症的药物及其制备方法 | |
CN104740345B (zh) | 治疗糖尿病的中药组合物及其制备方法 | |
CN107029124A (zh) | 一种用于治疗原发性高血压的中药组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20181130 |
|
WW01 | Invention patent application withdrawn after publication |